Treating Hereditary Thyroid Cancer in Children
Name of the Trial
Why This Trial Is Important
Surgery is the only curative therapy for patients with hereditary MTC. Patients whose tumors cannot be surgically removed (unresectable) or that recur following surgery need new treatment options.
In this trial, doctors are testing a new drug called vandetanib (Zactima) in young patients with advanced hereditary MTC. Vandetanib blocks the activity of the protein produced by the RET gene. Researchers believe that inhibiting the activity of the RET protein may cause tumors to shrink and reduce the levels of tumor biomarkers in patients with MTC. Besides looking for these treatment effects, doctors will assess the safety and the pharmacokinetics of vandetanib in these patients.
"MTC is the most common cause of death in patients with these genetic disorders, and the disease is relatively unresponsive to radiation therapy and standard or novel chemotherapeutic regimens," said Dr. Balis. "Vandetanib, unlike standard chemotherapy or radiation, specifically targets the genetic defect responsible for the development of these tumors."
Who Can Join This Trial
Study Site and Contact Information
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.